WO2009104556A1 - Composition - Google Patents

Composition Download PDF

Info

Publication number
WO2009104556A1
WO2009104556A1 PCT/JP2009/052548 JP2009052548W WO2009104556A1 WO 2009104556 A1 WO2009104556 A1 WO 2009104556A1 JP 2009052548 W JP2009052548 W JP 2009052548W WO 2009104556 A1 WO2009104556 A1 WO 2009104556A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
astringent skin
administered
test
skin extract
Prior art date
Application number
PCT/JP2009/052548
Other languages
English (en)
Japanese (ja)
Inventor
俊裕 中山
森　大輔
古川　昭栄
Original Assignee
株式会社岐阜セラツク製造所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社岐阜セラツク製造所 filed Critical 株式会社岐阜セラツク製造所
Publication of WO2009104556A1 publication Critical patent/WO2009104556A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A23K10/37—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms from waste material
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87—Re-use of by-products of food processing for fodder production

Definitions

  • the present invention relates to a composition applicable to, for example, foods, food additives, pharmaceuticals, feeds, pet foods and the like.
  • Depression patients increased from 440,000 in 1999 to 710,000 in 2002. Depression is also problematic because it is likely to lead to suicide if left untreated. Suicide has become a major social problem, with over 30,000 people for nine consecutive years until 2006, and it is said that depression is closely related to the background.
  • ⁇ ⁇ Not a few depression patients have anxiety disorders. Anxiety disorders are divided into obsessive-compulsive disorder, panic disorder, agoraphobia, acute stress disorder, generalized anxiety disorder, etc., depending on the symptoms. Panic disorder, a typical anxiety disorder, has a lifetime prevalence of 1.5 3.3%, approximately 30% are accompanied by depression, and the lifetime prevalence of depression in patients with panic disorder is more than 50%.
  • Alzheimer's disease a type of dementia, is estimated to take 4 to 6% over 65 years of age and over 15% over 80 years of age.
  • BDNF brain-derived neurotrophic factor
  • MAP kinase Activation of MAP kinase requires that both the threonine and tyrosine residues present between the kinase subdomains 7 and 8 are phosphorylated.
  • Non-patent Document 2 phosphorylated MAP kinase is decreased in the hippocampus and frontal cortex (Non-patent Document 2), which is considered to be useful for establishing short-term memory into long-term memory.
  • LTD long-term potentiation
  • Some drugs for treating depression have already been developed, but there are many problems. Although it is improving with the advent of a new generation of drugs, depression drugs currently used clinically have side effects such as gastrointestinal disorders and liver disorders, and are generally lacking in immediate action until the effects appear There is a problem that a certain period of time (2 to 3 weeks) is required. Benzodiazepine anti-anxiety drugs are used to treat anxiety disorders, but there are also problems such as drowsiness, lightheadedness, and dependence. Although various synthetic drugs have been developed for the treatment of Alzheimer's disease, side effects such as liver damage have been reported for acetylcholinesterase inhibitors, one of which has not yet been established. The current situation is not.
  • the present invention has been made in view of the above points, and provides a composition that can be used for treatment and prevention of cranial nerve diseases and brain function improvement, has few side effects, and is highly safe even when taken for a long time. With the goal.
  • the gist of the present invention is a composition containing one or more selected from the group consisting of treatment of cranial nerve disease, prevention of cranial nerve disease, and improvement of brain function, comprising peanut astringent skin and / or an extract thereof as an active ingredient. .
  • the composition of the present invention contains a peanut astringent skin, a peanut astringent skin extract, or both as an active ingredient, thereby having a cranial nerve disease therapeutic effect, a cranial nerve disease preventing effect, and a brain function improving effect.
  • the composition of the present invention is considered to exhibit the above-mentioned action because its active ingredient exhibits an activity similar to BDNF and has an action to enhance MAP kinase activation in brain neurons.
  • the highly safe natural product is used as an active ingredient, the composition of the present invention has few side effects and is highly safe even when taken for a long time.
  • Examples of the cranial nerve disease include one or more selected from the group consisting of depressive symptoms, anxiety symptoms, and memory disorders.
  • Examples of the brain function improvement include improvement of memory learning ability.
  • the composition may be, for example, any one of functional foods (for example, foods and drinks, food materials, health foods, foods for specified health use), food additives, pharmaceuticals, feeds, and pet foods. it can.
  • functional foods for example, foods and drinks, food materials, health foods, foods for specified health use
  • food additives for example, pharmaceuticals, feeds, and pet foods. it can.
  • the composition of the present invention has a BDNF-like action, and further has a BDNF gene expression enhancing action.
  • BDNF is known to have an effect of improving Alzheimer's disease and depressive symptoms. Therefore, Alzheimer's disease and depressive symptoms can be improved by using the composition of the present invention.
  • the dosage form and form of the composition according to the present invention are arbitrary, and can be used in the form of capsules, powders, granules, solids, liquids, gels and the like.
  • it can be set as the health food which has the form of a tablet or a capsule, and the pharmaceutical which has forms, such as a drink and a formulation.
  • the pharmaceutical which has forms, such as a drink and a formulation.
  • confectionery such as biscuits, cookies and candies
  • general food and drink such as sprinkles, vegetable juice, and soup.
  • it can also be used by appropriately mixing with feed or pet food.
  • Peanut (Arachis hypogaea LINENE) in the present invention is a plant belonging to the genus Legumeaceae, and is also called Nanjing beans, peanuts, and Tangjin beans.
  • Peanut astringent skin is also called thin skin or cuticle, but generally when peanuts are processed into various processed foods, most of them are removed and most are discarded.
  • the present invention makes effective use of this unused resource, astringent skin, and produces a composition with high added value (for example, pharmaceuticals, health foods, etc.), which can be said to be very significant in that respect.
  • the type of peanut in the present invention is not limited as long as it belongs to the genus Peanut, but peanut (A. hypogaea) that is generally widely used for food is preferable from the viewpoint of easy availability of raw materials. Also, there are no restrictions on the peanut production area and harvest time. Furthermore, the astringent skin can utilize what generate
  • the peeled skin peeled after processing processes, such as a heating process and a roasting process. Further, as a method of the molting process, there is a case where after peeling off the shell, the astringent skin is swelled by immersing in hot water and then peeling is performed. Since the active ingredient is dissolved in the hot water used at that time, the hot water can be used as a raw material of the composition according to the present invention. That is, after filtering hot water through a filter or the like as necessary, after concentration using a concentration means such as a vacuum concentration method, a normal pressure concentration method, or a thin film distillation method, a powdering means such as a freeze drying method or a spray drying method is used. And can be pulverized. Furthermore, if necessary, extraction and purification may be performed using a solvent such as ethanol described later. Further, purification means using an adsorbing resin described later may be combined.
  • a concentration means such as a vacuum concentration method, a normal pressure concentration method
  • a pulverized product can be obtained by pulverizing the astringent skin obtained from peanut, and this dried pulverized product can be used as an active ingredient in the present invention.
  • a drying method at this time a method generally used as a drying means such as hot air drying, vacuum drying, freeze drying, fluidized drying or the like can be used, and the method is not particularly limited.
  • a pulverization method a method generally used as a pulverization means such as dry pulverization, wet pulverization, and jet mill can be used, and the method is not particularly limited.
  • an astringent skin extract can be used as an active ingredient of the present invention.
  • the peeled astringent peel may be extracted as it is, but it is desirable to extract the raw material that has been crushed to an appropriate particle size in order to increase the extraction efficiency.
  • the solvent used for extraction for example, methanol, ethanol, propyl alcohol, isopropyl alcohol, butanol, isobutanol, etc., a single solvent selected from the group of butylene glycol, propylene glycol, glycerin, acetone, diethyl ether, ethyl acetate, Or any mixed solvent of two or more kinds of solvents, but when the extract is finally blended with food or the like, water, ethanol, or a mixed solvent thereof from the viewpoint of safety Is preferably used. Further, in order to improve the extraction rate, the extraction may be performed a plurality of times.
  • the ratio of the raw material (astringent skin) and the solvent at the time of extraction is not particularly limited, but is preferably 2 to 1000 parts of solvent with respect to 1 part of the raw material, particularly in terms of extraction operation and efficiency. It is preferred to use 5 to 100 parts of solvent per part.
  • the extraction temperature is not particularly limited, but it is convenient that the extraction temperature is in the range of room temperature to the boiling point of the solvent.
  • the extraction time varies depending on the extraction temperature, but is preferably in the range of 30 minutes to 24 hours.
  • the fraction obtained by purifying the active ingredient may be separated from the extract thus obtained, if necessary, using a separation technique such as column chromatography.
  • a separation technique such as column chromatography.
  • chromatography using a column or thin layer or membrane separation method can be used, and size exclusion chromatography such as gel permeation and gel filtration, distribution chromatography, adsorption chromatography, ion exchange chromatography, etc. The method can be used.
  • peanut astringent skin extract is dissolved in a small amount of water, water-containing methanol, water-containing ethanol or other solvent, and Sephadex LH-20 (trade name, manufactured by GE Healthcare Biosciences), Diaion HP-20 (The product is passed through a column packed with an adsorbent resin (trade name, manufactured by Mitsubishi Chemical Corporation), the active ingredient is adsorbed on the adsorbent resin, washed thoroughly with water, and the concentration and amount sufficient to elute the active ingredient.
  • the active ingredient may be eluted with a hydrophilic solvent such as methanol, ethanol or acetone, or a mixed solvent of these with water.
  • the extract or fraction is made into a concentrated solution using a concentration means such as a vacuum concentration method, a normal pressure concentration method, or a thin film distillation method, and then used as a powdered means such as a freeze drying method or a spray drying method. It can be pulverized.
  • a concentration means such as a vacuum concentration method, a normal pressure concentration method, or a thin film distillation method, and then used as a powdered means such as a freeze drying method or a spray drying method. It can be pulverized.
  • the active ingredient was eluted with 10 L of 40% ethanol, and fractions containing the active ingredient were collected and concentrated under reduced pressure at 40 ° C. to about 1/50 volume.
  • the concentrate was freeze-dried to obtain 115.8 g of peanut astringent skin extract.
  • the solution was intraperitoneally administered to 3 of the 4 mice so that the doses of peanut astringent skin extract were 30 ⁇ g / kg, 300 ⁇ g / kg, and 3000 ⁇ g / kg body weight, respectively.
  • PBS alone was administered to the remaining one mouse to serve as a control group.
  • mice hippocampus was removed, and the hippocampus was removed from RIPA buffer (150 mM sodium chloride, 20 mM Tris; pH 7.4, 2 mM ethylenediaminetetraacetic acid, 1% IGEPAL @ CA-630, 1% deoxycholic acid.
  • RIPA buffer 150 mM sodium chloride, 20 mM Tris; pH 7.4, 2 mM ethylenediaminetetraacetic acid, 1% IGEPAL @ CA-630, 1% deoxycholic acid.
  • FIG. 1 shows the results of the enhancement effect of phosphorylated MAP kinase in the hippocampus of mice when peanut astringent skin extract was administered intraperitoneally.
  • the vertical axis represents the ratio of phosphorylated MAP kinase and total MAP kinase.
  • mice administered with the peanut astringent skin extract was approximately 4.2 times the dose of 300 ⁇ g / kg and 3000 ⁇ g / kg of the dose compared to the hippocampus of mice (control) administered with PBS alone. It was confirmed that phosphorylation of MAP kinase was enhanced about 2.7 times.
  • test animals 6-week-old male ddY mice (Japan SLC) were purchased. The mice were divided into 6 groups and reared by free eating and drinking in a plastic gauge (width 280 mm ⁇ depth 440 mm ⁇ height 180 mm) as a rearing room. The breeding room was kept at room temperature 25 ⁇ 1 ° C. and lit from 7 o'clock to 19 o'clock.
  • mice After the mice were purchased and bred for 5 days, the tail suspension test described below was performed, and those with an immobilization time of 20 seconds or less or those with 2 minutes or more were excluded. The mice remaining in the selection were divided into 6 groups (6 mice in each group) from groups A to F so that the average immobilization time was equivalent.
  • FIG. 2 shows the immobilization time for each group.
  • shaft of FIG. 2 represents the immobilization time, and in FIG. 2, it represents with the average value +/- standard error of 6 animals in each group.
  • the method of applying stress to mice in Group B, Group D, and Group F is as follows. ine. 2006; 13: 658-67.
  • the mild stress method of) was partially modified and used as follows.
  • the mild stress load was started two days after the selection by the tail suspension test described above.
  • 15 minutes of forced swimming was performed on the mice of Group B, Group D, and Group F.
  • the animals were reared for 48 hours in an inclined cage, 24 hours in a filth cage, and 24 hours in a shaking cage.
  • the mice were rested without applying stress for 24 hours after applying various stresses.
  • the stress after the tilt cage was repeated three times.
  • Sample administration method The sample administration method was as follows.
  • Samples were administered to each group of mice by repeated oral administration once a day for 3 weeks from 48 hours after forced swimming under the above-mentioned mild stress load.
  • Samples to be administered were those in which the peanut astringent skin extract was dissolved in PBS for the groups C, D, E, and F. The dose was adjusted to 1 mg / kg body weight for groups C and D, and adjusted to 3 mg / kg body weight for groups E and F. For groups A and B, only PBS was administered.
  • (4) Method of tail suspension test After the sample was orally administered repeatedly for 3 weeks, the tail suspension test was performed on the mice of each group as follows. About 1 cm from the tip of the tail was picked with a fingertip, fixed at a height of 10 cm from the floor, and hung upside down.
  • FIG. 3 shows the results of the tail suspension test.
  • the vertical axis represents the immobilization time and is expressed as the average value ⁇ standard error of 6 animals in each group. ## mark in the figure indicates a significant difference in test values (## ⁇ 0.01) between the control group (Group A) administered with PBS alone and the stress group (Group B) administered with PBS alone. ). Also. * Mark indicates a significant difference in immobilization time between the stress group (group B) administered with PBS alone and the stress group (group F) administered with 3 mg / kg peanut astringent skin extract (p ⁇ 0.05).
  • the stress group administered with 1 mg / kg peanut astringent skin extract did not have a significant difference in the test values compared with the stress group administered with PBS alone (Group B), but decreased the immobilization time. I let you.
  • the stress group (F group) administered with 3 mg / kg peanut astringent peel significantly reduced the immobilization time. From this, the antidepressant effect was recognized by administration of 3 mg / kg peanut astringent skin extract.
  • (6) Method of glass ball cover test After the sample was orally administered repeatedly for 3 weeks, a glass ball cover test was performed on the mice of each group as follows.
  • Chips are laid out in a cage (width 300 mm x depth 300 mm x height 300 mm) made of a transparent acrylic plate so that the thickness is 5 cm, and 25 transparent glass balls with a diameter of 2 cm are placed between them. It was left 5 cm in length and width. After releasing the mouse into the cage and allowing it to move freely for 15 minutes, more than two-thirds of the glass balls covered with chips were counted. Using the decrease in the number of hidden glass balls as an index, the anxiolytic or anti-obsessive disorder and anti-panic disorder effects of the administered peanut astringent skin extract were evaluated. This glass ball covering test was carried out in the time zone from 8:00 to 11:00. (7) Results of Glass Ball Covering Test FIG.
  • the vertical axis indicates the number of hidden glass balls, and is expressed as an average value ⁇ standard error of 6 animals in each group.
  • the # mark in the figure indicates that there is a significant difference (# ⁇ 0.05) in the test value between the control group (Group A) administered with PBS alone and the stress group (Group B) administered with PBS alone. Indicates that there is. Also. * Mark indicates a significant difference in test values (*: p ⁇ ) between the stress group administered with PBS alone (Group B) and the stress group administered with 3 mg / kg peanut astringent skin extract (Group F). 0.05).
  • a cross board (width 5 cm x length 65 cm) intersecting at a right angle at the center is installed at a height of 60 cm from the floor, and a transparent acrylic with a height of 10 cm for a one-way board (closed arm). Both sides were partitioned with a metal plate. Release the mouse to this crossroad, let it move freely for 5 minutes, and the number of times it was in an arm (open arm) that was not partitioned by an acrylic board and the number of times it entered a board (closed arm) that was partitioned by an acrylic board Measured. The anxiolytic effect of the administered peanut astringent skin extract was evaluated using the length of time spent in the open arm as an index.
  • FIG. 6 shows the time each group of mice was in the open arm in the elevated plus maze test.
  • the vertical axis indicates the time spent in the open arm, and is expressed as the average value ⁇ standard error of 6 animals in each group.
  • the # mark in the figure indicates that there is a significant difference (# ⁇ 0.05) in the test value between the control group (Group A) administered with PBS alone and the stress group (Group B) administered with PBS alone. Indicates that there is.
  • * Mark indicates a significant difference in test values (*: p ⁇ ) between the stress group administered with PBS alone (Group B) and the stress group administered with 3 mg / kg peanut astringent skin extract (Group F). 0.05).
  • a line was drawn at regular intervals of 4 in the vertical direction and 4 in the horizontal direction on the floor of a cage made of white acrylic plates each having a width x depth x height of 40 cm, and the floor was divided into 16 equal parts.
  • the mouse was released into this cage and allowed to move freely for 5 minutes, and the time during which the mouse was in the middle 4 squares and the time during which the mouse was moving were measured.
  • the anxiolytic effect of the administered peanut astringent skin extract was evaluated using the length of time in the center as an index.
  • the effect of the peanut astringent skin extract on the amount of activity was evaluated using the time during which the mouse was moving as an index. This open field test was conducted in the time zone from 8:00 to 10:00.
  • a Y-shaped maze was used in which the total length of the arms was 40 cm, the wall height was 30 cm, the floor width was 5 cm, and the three arms were each connected at an angle of 120 degrees.
  • Mice were placed at the tip of any arm of the Y-maze 12 hours after the last sample administration, allowed to freely explore the maze for 8 minutes, and the arms selected by the mouse were recorded in the order of selection. The number of times the mouse selected each arm within the measurement time was recorded, and this was used as the total number of arm selections. Next, the combination which selected three different arms continuously from this was investigated, and this number was made into the number of replacement actions.
  • FIG. 8 shows the alternating action rate in the Y-shaped maze test.
  • the vertical axis represents the alternation behavior rate, and is expressed as an average value ⁇ standard error of 6 animals in each group.
  • the # mark in the figure indicates that there is a significant difference (# ⁇ 0.05) in the test value between the control group and the 3 mg / kg administration group.
  • mice were placed in the above-mentioned cage in which two wooden white spheres (diameter 3 cm) having the same shape were placed 10 cm apart from each other and 10 cm apart from each other. was released for 15 minutes to remember the two spheres.
  • replace one of the two spheres with a black cube (length x width x height 3 cm each) let the mouse stand in the cage for 10 minutes, and place the newly placed cube (new substance).
  • the time for searching and the time for searching for the stored sphere were measured.
  • the total search time is the sum of the time for searching for a new substance and the time for searching for a stored sphere.
  • the new substance search time is divided by the total search time and multiplied by 100 to obtain the new substance recognition index. Asked. A higher new substance recognition index indicates improved substance recognition memory with at least 24 hours of memory retention.
  • the novel substance recognition test was implemented in the time slot
  • FIG. 9 shows a new substance recognition index in the new substance recognition test.
  • the vertical axis represents the new substance recognition index, which is expressed as an average value ⁇ standard error of 5 animals in each group.
  • the # mark in the figure indicates that there is a significant difference (# ⁇ 0.05) in test values between the control group and the 1 mg / kg administration group.
  • the ## mark in the figure indicates that there is a significant difference in test values (## ⁇ 0.01) between the control group and the 3 mg / kg administration group.
  • the novel substance recognition index was significantly increased as compared with the control group.
  • the novel substance recognition index was significantly increased. From this, the working memory improvement effect by the peanut astringent skin extract was confirmed.
  • no improving action was observed.
  • mice in groups Y and Z were intraperitoneally administered once a day with sterile PBS (same amount as administered to group X) for 1 week.
  • (3) Administration of trimethyltin (TMT) TMT (trimethyltin chloride) dissolved in sterilized physiological saline is administered to the mice in groups X and Y at the last of the intraperitoneal administrations in (2) above.
  • the intraperitoneal administration was carried out the day after the administration.
  • the dose of TMT was 2.5 mg / kg body weight.
  • TMT is known to cause memory impairment similar to human Alzheimer's pathology (Pharmaceutical Journal. 2007 127 (3): 451-461) and forms a useful model of Alzheimer's disease. Only sterilized physiological saline was administered to the mice in group Z.
  • Y group group administered TMT but not peanut astringent extract
  • group Z no TMT administration group
  • memory impairment is induced.
  • Group X the group to which both TMT and peanut astringent skin extract were administered
  • group Y had a significantly increased alternation behavior rate and improved memory impairment by administering the peanut astringent skin extract compared to group Y. ing.
  • the # mark in FIG. 10 indicates that there is a significant difference (# ⁇ 0.05) in the test value between the Y group and the Z group.
  • * mark shows that there exists a significant difference (* ⁇ 0.05) in a test value between X group and Y group.
  • test method Fetal cerebral cortical neurons (hereinafter also simply referred to as nerve cells) taken from Wistar pregnant rats (gestation day 17; manufactured by SLC, Japan) were treated with poly-DL- It was housed in a 6-well plate coated with ornithine. This neuron was used at a density of 1 ⁇ 10 5 cells / cm 2 using medium 1 (Dulbecos's Modified Eagle's Medium (DMEM; manufactured by Invitrogen) containing 5% FBS, sodium selenite, antibiotics). Cultured for 24 hours. Thereafter, medium 1 was replaced with medium 2 (Neurobasal Medium (manufactured by Invitrogen) containing 2% B27 supplement, 1 mM sodium pyruvate, antibiotics, and 2 mM glutamine).
  • DMEM Dulbecos's Modified Eagle's Medium
  • the first group contained 30 ⁇ g of peanut astringent skin extract dissolved in sterile PBS.
  • the second group 100 ⁇ g / mL of peanut astringent skin extract dissolved in sterile PBS was added, and in the third group, only sterile PBS was added.
  • FIG. 11 shows the results of BDNF gene expression analysis by RT-PCR.
  • the vertical axis represents the ratio of BDNF and ⁇ -actin.
  • BDNF mRNA expression level was significantly increased in the nerve cells to which 30 ⁇ g / mL or 100 ⁇ g / mL of the peanut astringent skin extract was added, compared to the nerve cells to which only PBS was added.
  • tablet confectionery (food) was produced with the following composition.
  • Granulated sugar 85 parts
  • Concentrated fruit juice 5 parts
  • Example 2 ⁇ 53 parts by weight of the peanut astringent skin extract prepared in Example 1 was stirred and mixed with 17 parts by weight of lactose, 27 parts by weight of crystalline cellulose, and 3 parts by weight of sucrose fatty acid ester. 340 mg of this agitated and mixed product was compression molded to produce tablets (food, pharmaceuticals) having a diameter of 10 mm.
  • peanut astringent skin extract obtained in Example 1, drink (food) with the following composition Manufactured.
  • Peanut astringent skin extract 50mg Vitamin B1 30mg Vitamin C 50mg Citric acid 300mg Ethyl alcohol 500mg Fructose 3000mg Fragrance 100mg Water totaled 100ml
  • a pet food was produced with the following composition.
  • Chicken meal 22 parts by weight Dried chicory 2.5 parts by weight The rest consists of salt, vitamins and minerals.
  • peanut astringent skin for example, powder thereof
  • peanut astringent skin extract may be used instead of the peanut astringent skin extract.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)

Abstract

L'invention concerne une composition qui peut être utilisée pour le traitement ou la prévention d'une maladie nerveuse cérébrale et l'amélioration d'une fonction cérébrale, présente peu d'effets secondaires indésirables et est sans danger même lorsque la composition est administrée pendant une longue durée. La composition comprend une peau astringente d'une arachide et/ou un extrait de la peau astringente en tant qu'ingrédient actif, et peut être utilisée pour au moins une application choisie dans le groupe constitué par le traitement d'une maladie nerveuse cérébrale, la prévention d'une maladie nerveuse cérébrale et l'amélioration d'une fonction cérébrale. La maladie nerveuse cérébrale peut être au moins un élément choisi dans le groupe constitué par un état de dépression, un état d'anxiété et un trouble de la mémoire. L'amélioration d'une fonction cérébrale peut être l'amélioration d'une capacité de mémorisation/d'apprentissage. La composition peut être préparée dans un élément quelconque choisi parmi un produit alimentaire, un additif alimentaire, un produit pharmaceutique, un aliment pour animaux et un aliment pour animaux domestiques.
PCT/JP2009/052548 2008-02-19 2009-02-16 Composition WO2009104556A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008-037439 2008-02-19
JP2008037439 2008-02-19

Publications (1)

Publication Number Publication Date
WO2009104556A1 true WO2009104556A1 (fr) 2009-08-27

Family

ID=40985437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/052548 WO2009104556A1 (fr) 2008-02-19 2009-02-16 Composition

Country Status (2)

Country Link
JP (1) JP5443015B2 (fr)
WO (1) WO2009104556A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5754402B2 (ja) 2011-04-07 2015-07-29 信越化学工業株式会社 消泡剤用オイルコンパウンド及び消泡剤組成物
CN103933111A (zh) * 2013-05-02 2014-07-23 杭州耐奇睿生物医药科技有限公司 花生浸提物的应用
CN103877144B (zh) * 2013-05-02 2017-02-22 杭州耐奇睿生物医药科技有限公司 花生衣活性组分的应用及包含该花生衣活性组分的组合物
JPWO2017104706A1 (ja) * 2015-12-18 2018-10-04 国立大学法人富山大学 脳由来神経栄養因子の発現誘導剤及び組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532543A (ja) * 1998-12-18 2002-10-02 インデナ エッセ ピ ア 抗アテローム硬化剤としてのプロアントシアニジンａ２リン脂質複合体
JP2004026719A (ja) * 2002-06-25 2004-01-29 Maruzen Pharmaceut Co Ltd ピーナッツ渋皮抽出物を有効成分とする抗肥満用組成物
JP2005505497A (ja) * 2001-03-15 2005-02-24 プロテオテック・インコーポレーテッド アミロイド及びαシニュクライン疾患の治療のためのプロアントシアニジン
JP2008088131A (ja) * 2006-10-04 2008-04-17 Seishin Enterprise Co Ltd 抗コレステロール組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
JP2004329061A (ja) * 2003-05-02 2004-11-25 Puranzuboodo Soei:Kk ピーナッツの渋皮に含まれる抗酸化物質を発酵・抽出する方法
AU2006263430A1 (en) * 2005-06-29 2007-01-04 Mars, Incorporated Treatment of occlusive thrombosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532543A (ja) * 1998-12-18 2002-10-02 インデナ エッセ ピ ア 抗アテローム硬化剤としてのプロアントシアニジンａ２リン脂質複合体
JP2005505497A (ja) * 2001-03-15 2005-02-24 プロテオテック・インコーポレーテッド アミロイド及びαシニュクライン疾患の治療のためのプロアントシアニジン
JP2004026719A (ja) * 2002-06-25 2004-01-29 Maruzen Pharmaceut Co Ltd ピーナッツ渋皮抽出物を有効成分とする抗肥満用組成物
JP2008088131A (ja) * 2006-10-04 2008-04-17 Seishin Enterprise Co Ltd 抗コレステロール組成物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Proceedings of the Annual Meeting of the Pharmaceutical Society of Japan, 2007", vol. 54TH, article MEGUMI JINNO ET AL.: "Rakkasei Shuhi Yurai Proanthocyanidin no Kozo to Seiri Kassei ni Tsuite", pages: 208 *
ARUOMA, OKEZIE I. ET AL.: "Low molecular proanthocyanidin dietary biofactor Oligonol: Its modulation of oxidative stress, bioefficacy, neuroprotection, food application and chemoprevention potentials", BIOFACTORS, vol. 27, no. 1-4, 2006, pages 245 - 265 *
DATABASE CA accession no. STN Database accession no. 144:184610 *
HOANG VAN HA ET AL.: "PEANUT SKIN ANTIOXIDANTS", J FOOD LIPIDS, vol. 14, no. 3, 2007, pages 298 - 314 *
MURANO T. ET AL.: "Peanut extract reduces the increase in levels of malondialdehyde and carbonyl compounds in the brain formed during iron-induced epileptogenesis in rats", SEIKAGAKU, vol. 76, no. 8, 2004, pages 1118 *
SEIJI YAMAMOTO ET AL.: "Kinosei Shokuhin no Shin Sozai Peanut Shibukawa Chushutsubutsu no Seiri Sayo", JAPAN FOOD SCIENCE, vol. 46, no. 1, 2007, pages 39 - 43 *
TAN,YUZHI ET AL.: "Effects of GSP on learning and memory in mice", ZHONGGUO YAOLIXUE TONGBAO, vol. 20, no. 7, 2004, pages 804 - 807 *
TSUTOMU SASAKI ET AL.: "Peanut Shuhi Ekisu no Seiri Kino to sono Riyo", FOOD PROCESSING AND INGREDIENTS, vol. 35, no. 9, 2000, pages 60 - 62 *

Also Published As

Publication number Publication date
JP2009221188A (ja) 2009-10-01
JP5443015B2 (ja) 2014-03-19

Similar Documents

Publication Publication Date Title
JP6828054B2 (ja) ウォールナットオリゴペプチド粉、その調製方法と使用
JP2013241354A (ja) ホスホジエステラーゼ２阻害剤
JP5842640B2 (ja) ホスホジエステラーゼ３阻害剤
US20130261136A1 (en) Coffee extracts as ingredients of foods, drugs, cosmetics, dietary supplements, and biologics
JP5443015B2 (ja) 医薬組成物
JPWO2016163245A1 (ja) 筋肉細胞におけるエネルギー代謝活性化剤
KR20160147132A (ko) 오미자 잎 추출물을 함유하는 파킨슨 질환 또는 퇴행성 신경질환의 예방 또는 치료용 조성물
JP6133471B2 (ja) キサンチンオキシダーゼ阻害剤
JP7229513B2 (ja) 脳の機能改善剤および脳の機能改善用飲食品
JP5926616B2 (ja) 老化抑制剤
WO2018151334A1 (fr) Inhibiteur de xanthine oxydase et son procédé de production
JP6456714B2 (ja) 持久力向上剤
JP2022040231A (ja) キサンチンオキシダーゼ活性阻害用組成物
JP6462755B2 (ja) 脳の機能改善剤および脳の機能改善用飲食品
JP2012240996A (ja) 免疫賦活剤及び抗アレルギー剤並びにそれを含む食品、化粧品、医薬部外品及び動物飼料
JP5634062B2 (ja) 脳機能改善用組成物および脳機能を改善する方法
CN115737747B (zh) 一种用于改善记忆力、防治老年痴呆的中药组合物及其应用
JP6250433B2 (ja) 筋機能低下抑制剤
JP7254974B2 (ja) キサンチンオキシダーゼ活性阻害用組成物
JP7253764B2 (ja) 運動能力向上剤
JP2010235524A (ja) 花粉荷を含有する抗ヒスタミン剤
JP2002173434A (ja) 抗アレルギー性組成物
JPWO2007004570A1 (ja) 持久力向上および／または抗疲労作用を有する組成物
JP4867043B2 (ja) 酵母抽出分画物を用いた脳機能改善剤および食品
JP4714438B2 (ja) 抗疲労剤およびそれを含む飲食品

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09712420

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09712420

Country of ref document: EP

Kind code of ref document: A1